UK Approves Regeneron/Roche MAb Cocktail For COVID-19

Product Still Under Rolling Review At European Medicines Agency

The UK has pipped the EU to the post in granting a marketing authorization to what the health secretary describes as “a significant addition to our armoury to tackle COVID-19.”

COVID_Biosimilars
An antibody injection could help to treat and prevent COVID-19 infection • Source: Alamy

The UK regulator, the MHRA, has approved Regeneron Pharmaceuticals, Inc./Roche Holding AG’s monoclonal antibody combination, casirivimab plus imdevimab (REGN-COV), as Ronapreve for the treatment and prevention of COVID-19.

The move follows what the MHRA called a “thorough review of the evidence” and a recommendation from the government’s independent...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

Responsible Antimicrobial Manufacturing A Must For UK’s Subscription Model Applicants

 

The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.

Use AI In Health Technology Assessments Only When Valuable, England’s NICE Tells Pharma Firms

 

Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.

Leqembi's UK Rollercoaster: A Yes From MHRA, A No From NICE

 

While the drug regulator has approved Eisai/Biogen’s early Alzheimer’s disease treatment, the health technology assessment institute is worried that its benefits are too small to justify its costs – a concern that Eisai has pledged to address.

Working With The Inspectors: UK’s eXmoor Gets License To Make ATMPs

 

It is “absolutely fundamental” that manufacturers of cell and gene therapies interact with inspectors from regulatory agencies to understand their expectations around good manufacturing practice, a compliance consultant at CDMO eXmoor pharma says.

More from Europe

EU Biosimilar Filings, Opinions And Approvals

 
• By 

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

UK Expedites Cost Negotiations For Companies Conducting ATMP & Early Phase Trials

 

Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.

How To Decarbonize Pharma R&D

 

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.